Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Itolizumab in Subjects Hospitalized With COVID-19

X
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Itolizumab in Subjects Hospitalized With COVID-19

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itolizumab (Primary)
  • Indications COVID-19 pneumonia; COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUINOX
  • Sponsors Equillium
  • Most Recent Events

    • 25 Jan 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 25 Nov 2020 announced that due to the rapidly evolving COVID-19 treatment landscape, the According to an Equillium media release, company will not initiate this trial at this time due to the rapidly evolving COVID-19 treatment landscape.
    • 29 Oct 2020 According to an Equillium media release, Ivor S. Douglas is the principal investigator for this study. The interim assessments at 20% and 50% of enrollment are planned. More details about the trial will be provided at an upcoming Analyst Day that Equillium will be hosting on December 4, 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top